3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
7
Colorectal Neoplasms
5
Colonic Neoplasms
5
Rectal Neoplasms
4
Skin Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Thyroid Neoplasms
1
Solid Tumor
1
Rectal Diseases
1
Neoplasms
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Disease Progression
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colonic Diseases
1
Interventions
pembrolizumab
29
Carboplatin
27
Specimen Handling
21
durvalumab
20
Pemetrexed
18
Cisplatin
17
Paclitaxel
16
atezolizumab
15
Nivolumab
15
Magnetic Resonance Spectroscopy
15
osimertinib
11
Radiosurgery
11
Radiotherapy
10
Immunoglobulin G
10
Etoposide
10
Docetaxel
10
Disulfides
10
Radiation
9
Taxes
8
Gemcitabine
8
Biopsy
8
Blood Specimen Collection
7
Standard of Care
6
Practice Guidelines as Topic
6
Ipilimumab
6
Surveys and Questionnaires
5
Platinum
5
Bronchoscopy
5
Bevacizumab
5
Ramucirumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lung Neoplasms
×
encorafenib
×
Clear all
NCT05195632
2026-05-01
OCEANII
Pierre Fabre Medicament
Phase 2
Active not recruiting
63 enrolled